Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Texas Instruments Incorporated — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Texas Instruments Incorporated trades at $304.45 (market cap $266.93B). The key difference: Texas Instruments Incorporated is far larger — about 59.4× ACADIA Pharmaceuticals Inc.'s market cap, and Texas Instruments Incorporated pays a 1.94% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | TXN | |
|---|---|---|
Market Cap | $4.49B | $266.93B |
Sector | Health | Technology |
52-Week High | $28.06 | $332.35 |
52-Week Low | $20.06 | $153.33 |
Enterprise Value | $3.69B | $275.88B |
Dividend Yield | — | 1.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Texas Instruments (TXN) trades at $301.32, down 0.72% on the day, with technical indicators showing a bearish trend but recent news highlighting strong AI-driven demand. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in prior quarters, while maintaining robust profitability with a 29.11% net income margin. Revenue growth is recovering, projected to reach $18.4B in 2026, and the balance sheet shows solid liquidity with $7.58B in cash, though debt levels have risen.
Outlook: TXN benefits from AI infrastructure demand and operational leverage, but high valuation ratios (P/E 50.14) and rising debt pose risks. Analyst consensus is bullish with a $310.95 price target, suggesting modest upside potential. Key risks include competitive pressures and macroeconomic volatility affecting semiconductor cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
